Fluticasone propionate/salmeterol (Advair Diskus) vs indacaterol maleate / mometasone furoate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor · full Asthma pipeline
Fluticasone propionate/salmeterol (Advair Diskus)
Marketed by GlaxoSmithKline
NCT00920959 · Phase 3 · completed
This was a well-designed, randomized, double-blind, placebo-controlled trial with a reasonably large sample (908 participants) and a lung-function primary endpoint, which is the kind of objective physiological measure regulators accept for asthma trials. However, the key comparison -- showing that the fluticasone/salmeterol combination improved peak flow more than fluticasone alone -- did not reach statistical significance, so despite the strong design the result itself was a null finding rather than a demonstrated benefit.
Result from the sponsor's published study results summary; no peer-reviewed publication or posted CT.gov results were found.
Reported efficacy
Change from baseline at endpoint in daily PM PEF (12 weeks): Change in percent predicted PM PEF: FSC 100/50 QD did not give significantly greater improvement than FP 100 QD (superiority not shown) (missed)
Result source: NCT00920959
indacaterol maleate / mometasone furoate
Marketed by Novartis
NCT00557440 · Phase 2 · completed
The study was randomized and quadruple-blind, used both placebo and active control, and measured the clinically relevant lung-function endpoint FEV1. Although the primary comparison favored indacaterol/mometasone over placebo and was statistically significant, the small sample of 37 participants limits the strength of the evidence.
Next expected readout: February 2028 · NCT05562466 (registry estimate)
Reported efficacy
Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): Trough Forced Expiratory Volume in One Second (Trough FEV1) at Week 26 (26 weeks): QMF149 150/320 μg 2.383 litre (L) (Standard Error 0.0159) | QMF149 150/160 μg 2.387 litre (L) (Standard Error 0.016) | MF 800 μg 2.25 litre (L) (Standard Error 0.0162) | MF 400 μg 2.176 litre (L) (Standard Error 0.0162) | Salmeterol/Fluticasone 50/500 μg 2.346 litre (L) (Standard Error 0.016) (met)
Result source: NCT02554786
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Fluticasone propionate/salmeterol (Advair Diskus) | indacaterol maleate / mometasone furoate |
|---|---|---|
| Severe exacerbations, annualised rate | 2.6 vs 2.7vs FP DISKUSNCT00452348 | —Trial running · NCT05562466 |
| Trough FEV1, change | 0.1 vs 0.1vs FF/VINCT029246885 other results
| 0.1 vs -0.1+0.2 vs placeboNCT00557440 |
| ACQ-5, change | —Not posted · NCT00920959 | —Trial running · NCT05562466 |
| OCS dose reduction | —Not posted · NCT00920959 | —Trial running · NCT05562466 |
Severe exacerbations, annualised rate
- Fluticasone propionate/salmeterol (Advair Diskus)
- 2.6 vs 2.7vs FP DISKUSNCT00452348
- indacaterol maleate / mometasone furoate
- —Trial running · NCT05562466
Trough FEV1, change
- Fluticasone propionate/salmeterol (Advair Diskus)
- 0.1 vs 0.1vs FF/VINCT02924688
5 other results
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT02924688
- 0.2 vs 0.1 NCT02924688
- 0.1 vs -0.1 NCT00557440
- 0.2 vs 0.1 NCT00452348
- indacaterol maleate / mometasone furoate
- 0.1 vs -0.1+0.2 vs placeboNCT00557440
ACQ-5, change
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not posted · NCT00920959
- indacaterol maleate / mometasone furoate
- —Trial running · NCT05562466
OCS dose reduction
- Fluticasone propionate/salmeterol (Advair Diskus)
- —Not posted · NCT00920959
- indacaterol maleate / mometasone furoate
- —Trial running · NCT05562466
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Fluticasone propionate/salmeterol (Advair Diskus): 4 of 4 rows · indacaterol maleate / mometasone furoate: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Fluticasone propionate/salmeterol (Advair Diskus) | indacaterol maleate / mometasone furoate |
|---|---|---|
| Dropout rate | 0.2%a NCT01475721 · Phase 4 show 14 more results25.5%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 2.8%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 7.7%100/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.9%200/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence —100mcg/50mcg NCT00927758 · Phase 2 · registry result, not featured evidence — NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 | — NCT00557440 · Phase 2 · combination · Asthma · phase 2 show 1 more result0% NCT00605306 · Phase 2 · Asthma · phase 2 |
| Discontinued due to AEs | —a NCT01475721 · Phase 4 show 14 more results1.9%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence —50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 0.7%100/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0.7%200/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0.5%100/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0.5%200/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence —100mcg/50mcg NCT00927758 · Phase 2 · registry result, not featured evidence — NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 | — NCT00557440 · Phase 2 · combination · Asthma · phase 2 show 1 more result0% NCT00605306 · Phase 2 · Asthma · phase 2 |
| Serious AEs | 2.3%a NCT01475721 · Phase 4 show 14 more results2.3%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence 2%50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence 0%100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 1.9%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 4.4%100/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 5.1%200/62.5/25 mcg NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence 0%250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 0%250/50 mcg BID NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 0.6%100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 0%100mcg/50mcg NCT00927758 · Phase 2 · registry result, not featured evidence 0% NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 | 0% NCT00557440 · Phase 2 · combination · Asthma · phase 2 show 1 more result0% NCT00605306 · Phase 2 · Asthma · phase 2 |
| Most frequent reported AEs | show 14 more results250/50 mcg BID nasopharyngitis 17.4% headache 16.5% upper respiratory tract infection 14.5% NCT00452348 · Phase 4 · registry result, not featured evidence 50/100 mcg BD headache 18% nasopharyngitis 9.3% rhinitis 8% NCT00353873 · Phase 4 · registry result, not featured evidence 100/50mcg BID headache 3.2% upper respiratory tract infection 3.2% abdominal pain upper 2.4% NCT00118716 · Phase 4 · registry result, not featured evidence 50/12.5 mcg BID nasopharyngitis 4.3% (placebo 5.3%) NCT02980133 · Phase 3 · registry result, not featured evidence 100/31.25/25 mcg nasopharyngitis 13.8% headache 7.7% upper respiratory tract infection 5.9% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 200/31.25/25 mcg nasopharyngitis 12.6% headache 6.7% bronchitis 4% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 14.8% headache 8.9% bronchitis 3.7% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 200/62.5/25 mcg nasopharyngitis 12.5% bronchitis 5.4% headache 4.7% NCT02924688 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 250/50 mcg BID headache 11% hypertension 6.1% blood pressure increased 0% NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 250/50 mcg BID headache 12.2% hypertension 4.9% blood pressure increased 3.7% NCT01978119 · Phase 3 · registry result, not featured evidence · monotherapy · Asthma · phase 3 100/50 HFA headache 15% nasopharyngitis 9.2% upper respiratory tract infection 6.4% NCT00441441 · Phase 3 · registry result, not featured evidence 100mcg/50mcg cough 5% upper respiratory infection 5% viral upper respiratory infection 5% NCT00927758 · Phase 2 · registry result, not featured evidence headache 5.6% (placebo 5.4%) NCT00557440 · Phase 2 · registry result, not featured evidence · Asthma · phase 2 | headache 5.6% (placebo 5.4%) NCT00557440 · Phase 2 · combination · Asthma · phase 2 show 1 more resultcough 35.7% (placebo 14.3%) headache 35.7% (placebo 14.3%) bronchitis 14.3% (placebo 0%) NCT00605306 · Phase 2 · Asthma · phase 2 |
Notes
- aPopulation comparability has not been reviewed for 8 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Fluticasone propionate/salmeterol (Advair Diskus)
show 2 more results
+ 22 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Fluticasone propionate/salmeterol (Advair Diskus)'s landscape · indacaterol maleate / mometasone furoate's landscape